Journal
GENES
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/genes13081308
Keywords
epigenetics; Alzheimer's disease; biomarkers
Categories
Ask authors/readers for more resources
Alzheimer's disease is a progressive neurodegenerative disorder that leads to cognitive impairment and dementia in older individuals. Detection of altered epigenetic signatures in blood may assist in the early diagnosis and treatment of the disease.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and represents the leading cause of cognitive impairment and dementia in older individuals throughout the world. The main hallmarks of AD include brain atrophy, extracellular deposition of insoluble amyloid-beta (A beta) plaques, and the intracellular aggregation of protein tau in neurofibrillary tangles. These pathological modifications start many years prior to clinical manifestations of disease and the spectrum of AD progresses along a continuum from preclinical to clinical phases. Therefore, identifying specific biomarkers for detecting AD at early stages greatly improves clinical management. However, stable and non-invasive biomarkers are not currently available for the early detection of the disease. In the search for more reliable biomarkers, epigenetic mechanisms, able to mediate the interaction between the genome and the environment, are emerging as important players in AD pathogenesis. Herein, we discuss altered epigenetic signatures in blood as potential peripheral biomarkers for the early detection of AD in order to help diagnosis and improve therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available